General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Imago BioSciences on Its Upsized Initial Public Offering

July 21, 2021
A multidisciplinary team advises the clinical stage biopharmaceutical company in the offering.

Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), has announced the closing of US$134.4 million in gross proceeds from its previously announced initial public offering and US$20 million in gross proceeds from its concurrent private placement.

The initial public offering of 8,400,000 shares of common stock at a public offering price of US$16 per share resulted in aggregate gross proceeds to Imago of US$134.4 million, before deducting underwriting discounts, commissions and offering expenses. All of the shares in the initial public offering were offered by Imago.

Latham & Watkins LLP represents Imago BioSciences, Inc. in the offering with a corporate deal team led by Bay Area partners Ben Potter and Rick Kline, with associates Tess Bloom, Taimi Jacobson and Ajay Sundar. Advice was also provided on healthcare and life sciences regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Los Angeles associate Leia Gu; on benefit and compensation matters by Bay Area partner Jay Metz; on intellectual property matters by Bay Area partner Judith Hasko, with associate Stephanie Blij; and on tax matters by Bay Area partner Katharine Moir.